Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Lantheus Holdings, Inc. - Common Stock (NQ: LNTH )

79.94 -2.02 (-2.46%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 737,436
Open 82.55
Bid (Size) 79.95 (1)
Ask (Size) 90.70 (1)
Prev. Close 81.96
Today's Range 79.91 - 83.42
52wk Range 56.06 - 126.89
Shares Outstanding 67,604,097
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Lantheus to Host Fourth Quarter and Full Year 2024 Earnings Conference Call and Webcast on February 26, 2025, at 8:00 a.m. Eastern Time
From Lantheus Holdings, Inc.
Via GlobeNewswire
Lantheus Announces Presentations Featuring PYLARIFY (Piflufolastat F 18) Data at the ASCO GU Meeting
From Lantheus Holdings, Inc.
Via GlobeNewswire

Performance

YTD
-9.98%
-9.98%
1 Month
-12.71%
-12.71%
3 Month
+4.88%
+4.88%
6 Month
-18.31%
-18.31%
1 Year
+39.12%
+39.12%

More News

Read More
NASDAQ:LNTH is showing decent growth, but is still valued reasonably.
Via Chartmill
Lantheus Appoints Phuong Khanh (P.K.) Morrow, M.D., as New Board Member
From Lantheus Holdings, Inc.
Via GlobeNewswire
What 4 Analyst Ratings Have To Say About Lantheus Holdings
Via Benzinga
Why Lantheus Holdings (LNTH) Stock Is Down 4%
Via Benzinga
NASDAQ:LNTH is probably undervalued for the fundamentals it is displaying.
Via Chartmill
Why Lantheus Holdings Stock Got Thrashed on Tuesday
Via The Motley Fool
9 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Lantheus To Buy Evergreen Theragnostics For Over $1 Billion To Bolster Its Cancer Radiopharmaceutical Portfolio
Via Benzinga
Why NASDAQ:LNTH Is a Standout High-Growth Stock in a Consolidation Phase.
Via Chartmill
Exploring the Growth Potential of NASDAQ:LNTH as It Nears a Breakout.
Via Chartmill
$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today
Via Benzinga
P/E Ratio Insights for Lantheus Holdings
Via Benzinga
Here's How Much You Would Have Made Owning Lantheus Holdings Stock In The Last 5 Years
Via Benzinga
Lantheus to Acquire Evergreen Theragnostics for Upfront Payment of $250 Million to Drive Strategic Evolution into Fully Integrated Radiopharmaceutical Leader
From Lantheus Holdings, Inc.
Via GlobeNewswire
Deal Dispatch: Biden Punts TikTok Ban To Trump, Plus Another Legacy Retailer Goes Bankrupt
Via Benzinga
Topics Government
Exposures Political
Lantheus to Acquire Life Molecular Imaging for an Upfront Payment of $350 Million to Accelerate Innovation for Patients in the Growing Alzheimer’s Disease Radiodiagnostic Market
From Lantheus Holdings, Inc.
Via GlobeNewswire
NASDAQ:LNTH is showing decent growth, but is still valued reasonably.
Via Chartmill
Lantheus Stock Doubled In A Year Amid Wide Use Of Its AI-Enabled Medical Devices
Via Investor's Business Daily
For those who appreciate value investing, NASDAQ:LNTH is a compelling option with its solid fundamentals.
Via Chartmill
2 Stock Market Predictions for 2025: 2 Stocks Worth Buying No Matter What Happens
Via The Motley Fool
For those who appreciate growth without the sticker shock, NASDAQ:LNTH is worth considering.
Via Chartmill
This Box Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Via Benzinga
Why NASDAQ:LNTH Is a Promising High-Growth Stock in the Midst of Consolidation.
Via Chartmill
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.